Use your browser's back button to choose another title or click here for a New Search.

How to Get the Poster

 Download PDF (free)


Bookmark and Share





Baseline Characteristics by Randomization Status in NIDA-CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT).

Poster presented at the College on Problems of Drug Dependence (CPDD) annual meeting, Montreal, Canada, June 17-22, 2017

Jeanine May, PhD (Emmes Corporation), Dagmar Salazar, MS (Emmes Corporation), Patricia Novo, MPA, MPH (NYU School of Medicine, GNY Node), Dikla Shmueli-Blumberg, PhD (Emmes Corporation), Jacquie King, MS (Emmes Corporation), Abigail G. Matthews, PhD (Emmes Corporation), John Rotrosen, MD (NYU School of Medicine).

NIDA-CTN-0051 is a multi-center, two-arm, 6-month (24-week), parallel-group, open-label randomzied controlled trial to examine the comparative effectiveness and safety of extended-release naltrexone (XR-NTX) versus buprenorphine+naloxone (BUP-NX). Thi study is intended to develop an evidence-base to help patients and providers make informed choices and to foster wider adoption of relapse-prevention pharmacotherapies. This poster reports on the study participant enrollment process for CTN-0051, from consent to the point of randomization, comparing randomized vs. not randomized participants for baseline demographics, motivations for participating in the study, and attitudes about study medication.

After analysis, the greatest difference between the two groups appeared to be the role of access to medication as a motivating factor (endorsed by 39% of the not randomized group vs. only 16% of the randomized group). After assessing the motivations and attitudes about treatment, it also appeared that the preference for BUP-NX was stronger than that for XR-NTX. However, motivations and attitudes toward treatment were not collected for all the not randomized participants (before they dropped out of the treatment setting or screening). Conclusions about motivations for the not randomized group may not be generalizable. Overall, the two groups were quite similar. (Poster, PDF, English, 2017)

Keywords: Buprenorphine/Naloxone | CTN platform/ancillary study | Naltrexone | Opioid dependence | Pharmacological therapy | College on Problems of Drug Dependence (CPDD) annual meeting, 2017

Document No: 1324.

Submitted by Patricia Novo, GNY Node, 7/30/2018.

King, Jacquie mail
Matthews, Abigail G.
May, Jeanine
Novo, Patricia
Rotrosen, John
Salazar, Dagmar
Shmueli-Blumberg, Dikla
NIDA-CTN-0051 www

dark blue line
Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 7/2018 --
dark blue line